Healthcare-focused GP Lily Asia Ventures and SBCVC have participated in a RMB100 million ($15 million) Series A round for 360 Haoyao, an online drug seller established by Chinese software company Qihoo360 Technology.
Healthcare specialist Vivo Capital has closed its latest Sino-US venture capital fund with around $100 million in commitments. The vehicle will focus on early-stage investments.
The International Finance Corporation (IFC), the investment arm of the World Bank, has committed $68 million to Indian clinic chain Apollo Health and Lifestyle (AHL).
Ping An Good Doctor, a healthcare-focused mobile app controlled by Chinese Ping An Insurance Group, has raised $500 million in a Series A round of funding at a valuation of $3 billion.
WI Harper Group has closed its eighth venture capital fund, which targets early-stage investments in Asia-focused companies, at $175 million.
Hong Kong-listed drug maker Fosun Pharmaceutical has made a non-binding proposal to acquire Gland Pharma, an Indian pharmaceutical developer backed by KKR.
China Everbright has acquired a 67.3% stake in Beijing Huichen Nursing Home Management, a healthcare services provider for more than 10,000 Chinese seniors.
Tower Capital, a vehicle controlled by former 3i and Actis Capital Partners executive Danny Koh, is partnering with Temasek Holdings in a S$269 million ($196 million) takeover bid for traditional Chinese medicine (TCM) operator Eu Yan Sang International.
CDH Investments has made another partial exit from China-based drug developer Luye Pharma, generating proceeds of between HK$709 million ($91.4 million) and HK$729 million.
Japanese oncology specialist Taiho Pharmaceutical has launched a VC arm that will invest an initial pool of $50 million in global start-ups focused on cancer therapies.
Gu Sheng Tang, a traditional Chinese medicine (TCM) clinic chain, has raised $70 million in a Series C round led by US-based insurance firm Starr Companies, followed by China Ping An Insurance.
IDG Ventures, Inventus Capital and Blume Ventures have led a $6 million Series A round for Indian health and fitness app developer HealthifyMe.
Taiwan-based ACT Genomics will use its Series B funding to expand its genetic sequencing and molecular testing services - typically used by doctors in cancer treatment - to other Asian markets
Warburg Pincus has invested an undisclosed sum in UIB, a Shanghai-based hospital chain that focuses on obstetrics, gynecology and pediatrics.
Hotung Group and CDIB Capital has led a $12.5 million Series B round of funding for ACT Genomics, a Taiwan-based company that provides information to cancer treatment specialists.
Sino-US biopharmaceutical company Sirnaomics has raised $10 million in a Series B round led by Hong Kong-based venture capital firm Value Measured Investment.
The International Finance Corporation (IFC) has led a INR4 billion ($60 million) Series D round of funding for Indian online eyewear retailer Lenskart.
TPG Capital has bought a majority stake in Cancer Treatment Services International (CTSI), a US cancer treatment chain focused on India and South Asia. AVCJ understands that the firm paid $33 million for a 65% interest.
Following its $50 million Series C round, investors in Hua Medicine are waiting for the company to fulfill its potential as a poster child of innovation in China
Harvest Fund Management has led a $50 million Series C round – which was more than 3x oversubscribed – for China-based clinical-stage diabetes treatment developer Hua Medicine.
China-focused GP Qiming Venture Partners is planning to raise a healthcare-dedicated fund in the US that will help China- and US-based start-ups expand in both markets.
Maverick Capital Ventures, the VC affiliate of hedge fund Maverick Capital, has led a INR1 billion ($15 million) Series B round for Indian online pharmaceutical platform 1mg.
San Diego-based cancer treatment developer Sorrento Therapeutics has raised about $150 million from a group of investors led by China-focused healthcare specialist Ally Bridge Group.
Samara Capital has paid INR1.51 billion ($22.7 million) for the Indian division of South African drug maker Adcock Ingram Holdings.